Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
暂无分享,去创建一个
A. Schneeweiss | M. Parmar | J. Mackey | D. Cameron | X. Pivot | C. Jackisch | R. Bell | G. Steger | T. Suter | N. Masuda | L. Vanlemmens | P. Hall | M. Toi | Julia M. Brown | R. Dent | R. Hegg | L. Provencher | L. Morales | F. Overkamp | A. Kirsch | N. Xu
[1] D. Miles,et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. , 2017, European journal of cancer.
[2] J. Balko,et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.
[3] E. Perez,et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer , 2016, Breast Cancer Research and Treatment.
[4] J. Manola,et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.
[5] P. Hegde,et al. Abstract S1-01: Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC) , 2016 .
[6] H. Iwata,et al. Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) , 2016 .
[7] S. Paik,et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. , 2015, The Lancet. Oncology.
[8] R. Kerbel,et al. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy , 2015, Clinical Cancer Research.
[9] C. Caldas,et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[10] P. Maini,et al. Mesoscopic and continuum modelling of angiogenesis , 2014, Journal of mathematical biology.
[11] D. Berry,et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Doval,et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[13] F. Puglisi,et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[14] M. Rezai,et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] W. Gradishar,et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. , 2014 .
[16] P. Carmeliet,et al. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. , 2014, Pharmacology & therapeutics.
[17] M. Buyse,et al. Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer , 2013 .
[18] M. Parmar,et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[19] J. Pérez-García,et al. Adjuvant bevacizumab: positive data from a negative trial. , 2013, The Lancet. Oncology.
[20] R. Kerbel,et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. , 2013, Breast.
[21] N. Petrelli,et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Hecht,et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.
[23] J. Baselga,et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Tanja Fehm,et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.
[25] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[26] E. Perez,et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Arlene Chan,et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[31] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[32] I. Fidler,et al. Cancer metastasis. , 1991, British medical bulletin.
[33] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.